<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990314</url>
  </required_header>
  <id_info>
    <org_study_id>BPS-MR-PAH-204</org_study_id>
    <nct_id>NCT00990314</nct_id>
  </id_info>
  <brief_title>Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients</brief_title>
  <official_title>An Open-label Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lung Biotechnology PBC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lung Biotechnology PBC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study for patients who participated in the BPS-MR-PAH-203 study and
      have volunteered to continue treatment for PAH with Beraprost Sodium Modified Release
      (BPS-MR) tablets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients who participated in BPS-MR-PAH-203 and who elect to continue receiving
      study drug in an open-label extension.Each patient will return to the clinic following
      enrollment in the study at 3, 6, and 12 months, and annually thereafter for assessment.
      Patients will be called by study personnel to assess adverse events and concomitant
      medications at Month 9, and at 3 month intervals following the annual visit.

      At the End of Study visit, patients discontinuing study drug will be down-titrated off of
      BPS-MR at the discretion of the Investigator, at a maximum decrement of one tablet (60µg)
      b.i.d. per day and a minimum decrement of one tablet (60µg) b.i.d. per week. Likewise,
      patients who withdraw early from the study will be down-titrated off of BPS-MR in the same
      manner. Upon completion of down-titration, patients will return to the clinic for a final
      Closeout visit.

      Currently enrolled patients may be invited to participate in an optional four times daily
      (QID) dosing substudy of BPS-MR with total daily dose of BPS-MR achieved previously in the
      main study. Patients will return to the clinic for baseline visit, week 12, and then will
      follow the visit schedule provided to them in BPS-MR-PAH-204 main study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety will be assessed by adverse events, physical examination, vital signs, clinical laboratory parameters, and electrocardiogram findings.</measure>
    <time_frame>3, 6 &amp; 12 months &amp; annually thereafter</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unencouraged 6-Minute Walk Test (6MWT)</measure>
    <time_frame>3, 6 &amp; 12 months &amp; annually thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Worsening</measure>
    <time_frame>3, 6 &amp; 12 months &amp; annually thereafter</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>B.I.D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beraprost Sodium Modified Release Tablet, 60mcg, B.I.D (twice a day dosing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Q.I.D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beraprost Sodium Modified Release Tablet, 60mcg, q.i.d (four times a day dosing)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beraprost Sodium Modified Release</intervention_name>
    <arm_group_label>B.I.D</arm_group_label>
    <arm_group_label>Q.I.D</arm_group_label>
    <other_name>BPS-MR Tablets, 60mcg</other_name>
    <other_name>Beraprost Sodium Modified Release Tablet, 60mcg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who remained on study drug and completed all assessments during the Treatment
             Phase of Study BPS MR PAH 203 are eligible for this study.

          -  Women of child-bearing potential (defined as less than 1 year post-menopausal or not
             surgically sterile) must be using an acceptable method of birth control or practicing
             abstinence. If sexually active, female patients must use a double barrier method of
             birth control, such as a condom and spermicidal.

        Exclusion Criteria:

          -  Patients who discontinued study drug during the previous study (BPS MR PAH 203) for
             any reason (e.g. treatment related adverse events) are not eligible for entry into
             this study.

          -  Patients who are pregnant or lactating are excluded from participation in the
             open-label extension.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aimee Smart</last_name>
    <role>Study Director</role>
    <affiliation>Study Sponsor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Heart Foundation - Advocate Medical Group</name>
      <address>
        <city>Oakbrook Terrace</city>
        <state>Illinois</state>
        <zip>60181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universite Libre de Bruxelles</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Teaching Hospital</name>
      <address>
        <city>Praha</city>
        <zip>2, 128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitat zu Koln</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abt Innere Medizin III, Medizinische Universitatsklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Leipzig Abteilung Pulmologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital Ltd.</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul de Urgenta pentru Boli</name>
      <address>
        <city>Bucuresti</city>
        <zip>022322</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul National de Pneumologie</name>
      <address>
        <city>Bucuresti</city>
        <zip>050159</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul de Boli Cardiovasculare</name>
      <address>
        <city>Lasi</city>
        <zip>700503</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2009</study_first_submitted>
  <study_first_submitted_qc>October 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2009</study_first_posted>
  <disposition_first_submitted>February 11, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>February 11, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 13, 2014</disposition_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beraprost</mesh_term>
    <mesh_term>Epoprostenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

